Literature DB >> 22434036

Use of interferon-γ enzyme-linked immunospot assay to characterize novel T-cell epitopes of human papillomavirus.

Xuelian Wang1, William W Greenfield, Hannah N Coleman, Lindsey E James, Mayumi Nakagawa.   

Abstract

A protocol has been developed to overcome the difficulties of isolating and characterizing rare T cells specific for pathogens, such as human papillomavirus (HPV), that cause localized infections. The steps involved are identifying region(s) of HPV proteins that contain T-cell epitope(s) from a subject, selecting for the peptide-specific T cells based on interferon-γ (IFN-γ) secretion, and growing and characterizing the T-cell clones (Fig. 1). Subject 1 was a patient who was recently diagnosed with a high-grade squamous intraepithelial lesion by biopsy and underwent loop electrical excision procedure for treatment on the day the T cells were collected(1). A region within the human papillomavirus type 16 (HPV 16) E6 and E7 proteins which contained a T-cell epitope was identified using an IFN- g enzyme-linked immunospot (ELISPOT) assay performed with overlapping synthetic peptides (Fig. 2). The data from this assay were used not only to identify a region containing a T-cell epitope, but also to estimate the number of epitope specific T cells and to isolate them on the basis of IFN- γ secretion using commercially available magnetic beads (CD8 T-cell isolation kit, Miltenyi Biotec, Auburn CA). The selected IFN-γ secreting T cells were diluted and grown singly in the presence of an irradiated feeder cell mixture in order to support the growth of a single T-cell per well. These T-cell clones were screened using an IFN- γ ELISPOT assay in the presence of peptides covering the identified region and autologous Epstein-Barr virus transformed B-lymphoblastoid cells (LCLs, obtained how described by Walls and Crawford)(2) in order to minimize the number of T-cell clone cells needed. Instead of using 1 x 10(5) cells per well typically used in ELISPOT assays(1,3), 1,000 T-cell clone cells in the presence of 1 x 10(5) autologous LCLs were used, dramatically reducing the number of T-cell clone cells needed. The autologous LCLs served not only to present peptide antigens to the T-cell clone cells, but also to keep a high cell density in the wells allowing the epitope-specific T-cell clone cells to secrete IFN-γ. This assures successful performance of IFN-γ ELISPOT assay. Similarly, IFN- γ ELISPOT assays were utilized to characterize the minimal and optimal amino acid sequence of the CD8 T-cell epitope (HPV 16 E6 52-61 FAFRDLCIVY) and its HLA class I restriction element (B58). The IFN- γ ELISPOT assay was also performed using autologous LCLs infected with vaccinia virus expressing HPV 16 E6 or E7 protein. The result demonstrated that the E6 T-cell epitope was endogenously processed. The cross-recognition of homologous T-cell epitope of other high-risk HPV types was shown. This method can also be used to describe CD4 T-cell epitopes(4).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22434036      PMCID: PMC3460593          DOI: 10.3791/3657

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  14 in total

Review 1.  Immune control of HIV: the obstacles of HLA and viral diversity.

Authors:  B D Walker; B T Korber
Journal:  Nat Immunol       Date:  2001-06       Impact factor: 25.606

2.  Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern Africa.

Authors:  Agatha M Masemola; Tumelo N Mashishi; Greg Khoury; Helba Bredell; Maria Paximadis; Tiyani Mathebula; Debra Barkhan; Adrian Puren; Efthyia Vardas; Mark Colvin; Lynn Zijenah; David Katzenstein; Rosemary Musonda; Susan Allen; Newton Kumwenda; Taha Taha; Glenda Gray; James McIntyre; Salim Abdool Karim; Haynes W Sheppard; Clive M Gray
Journal:  J Immunol       Date:  2004-10-01       Impact factor: 5.422

3.  T cell epitope "hotspots" on the HIV Type 1 gp120 envelope protein overlap with tryptic fragments displayed by mass spectrometry.

Authors:  Scott A Brown; Timothy D Lockey; Clive Slaughter; Karen S Slobod; Sherri Surman; Amy Zirkel; Ashutosh Mishra; Vishwajeeth R Pagala; Chris Coleclough; Peter C Doherty; Julia L Hurwitz
Journal:  AIDS Res Hum Retroviruses       Date:  2005-02       Impact factor: 2.205

4.  Cytotoxic CD8+ T cells recognize EBV antigen but poorly kill autologous EBV-infected B lymphoblasts: immunodominance is elicited by a peptide epitope that is presented at low levels in vitro.

Authors:  Y Shi; K D Smith; M G Kurilla; C T Lutz
Journal:  J Immunol       Date:  1997-08-15       Impact factor: 5.422

5.  Patterns of CD8 T-cell epitopes within the human papillomavirus type 16 (HPV 16) E6 protein among young women whose HPV 16 infection has become undetectable.

Authors:  Mayumi Nakagawa; Kevin H Kim; Anna-Barbara Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

6.  A high-throughput single-cell analysis of human CD8⁺ T cell functions reveals discordance for cytokine secretion and cytolysis.

Authors:  Navin Varadarajan; Boris Julg; Yvonne J Yamanaka; Huabiao Chen; Adebola O Ogunniyi; Elizabeth McAndrew; Lindsay C Porter; Alicja Piechocka-Trocha; Brenna J Hill; Daniel C Douek; Florencia Pereyra; Bruce D Walker; J Christopher Love
Journal:  J Clin Invest       Date:  2011-10-03       Impact factor: 14.808

7.  HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein.

Authors:  Mayumi Nakagawa; Kevin H Kim; Tiffany M Gillam; Anna-Barbara Moscicki
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

8.  Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6.

Authors:  M Evans; L K Borysiewicz; A S Evans; M Rowe; M Jones; U Gileadi; V Cerundolo; S Man
Journal:  J Immunol       Date:  2001-11-01       Impact factor: 5.422

9.  Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia.

Authors:  M Nakagawa; D P Stites; S Farhat; J R Sisler; B Moss; F Kong; A B Moscicki; J M Palefsky
Journal:  J Infect Dis       Date:  1997-04       Impact factor: 5.226

10.  Different methods of identifying new antigenic epitopes of human papillomavirus type 16 E6 and E7 proteins.

Authors:  Mayumi Nakagawa; Kevin H Kim; Anna-Barbara Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2004-09
View more
  5 in total

1.  A Human Papillomavirus Type 16 E6 52-62 CD4 T-Cell Epitope Restricted by the HLA-DR11 Molecule Described in an Epitope Hotspot.

Authors:  Hannah N Coleman; Xuelian Wang; William W Greenfield; Mayumi Nakagawa
Journal:  MOJ Immunol       Date:  2014

Review 2.  Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines.

Authors:  Mayumi Nakagawa; William Greenfield; Andrea Moerman-Herzog; Hannah N Coleman
Journal:  Clin Vaccine Immunol       Date:  2015-05-06

3.  A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3.

Authors:  William W Greenfield; Shawna L Stratton; Rebecca S Myrick; Rita Vaughn; Lisa M Donnalley; Hannah N Coleman; Maria Mercado; Andrea M Moerman-Herzog; Horace J Spencer; Nancy R Andrews-Collins; Wilbur C Hitt; Gordon M Low; Nirvana A Manning; Samantha S McKelvey; Dora Smith; Michael V Smith; Amy M Phillips; C Matthew Quick; Susanne K Jeffus; Laura F Hutchins; Mayumi Nakagawa
Journal:  Oncoimmunology       Date:  2015-05-27       Impact factor: 8.110

4.  Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed.

Authors:  Takeo Shibata; Sumit Shah; Teresa Evans; Hannah Coleman; Benjamin J Lieblong; Horace J Spencer; Charles M Quick; Toshiyuki Sasagawa; Owen W Stephens; Erich Peterson; Donald Johann; Yong-Chen Lu; Mayumi Nakagawa
Journal:  Front Immunol       Date:  2021-09-30       Impact factor: 7.561

5.  A novel prostate cancer immunotherapy using prostate-specific antigen peptides and Candida skin test reagent as an adjuvant.

Authors:  Al-Ola Abdallah; Hannah Coleman; Mohamed Kamel; Rodney Davis; Teri Landrum; Horace Spencer; Sam Mackintosh; Fade A Mahmoud; Natasa Milojkovic; Chester Wicker; Konstantinos Arnaoutakis; Mayumi Nakagawa
Journal:  SAGE Open Med       Date:  2018-09-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.